A Phase 1, Multiple-Dose Study of the Safety, Tolerability, and Pharmacokinetics of TAK-700 in Hormone Therapy-Resistant Prostate Cancer Subjects

Trial Profile

A Phase 1, Multiple-Dose Study of the Safety, Tolerability, and Pharmacokinetics of TAK-700 in Hormone Therapy-Resistant Prostate Cancer Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 27 Apr 2017

At a glance

  • Drugs Orteronel (Primary) ; Prednisolone
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Sponsors Takeda
  • Most Recent Events

    • 28 Oct 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top